父亲使用炎症性肠病药物与子代医院诊断感染风险:一项全国性队列研究
基于丹麦健康登记处的全国性队列研究,纳入1997年1月至2019年2月出生的、父亲患有炎症性肠病的所有活产单胎儿童。暴露组为父亲在受孕前3个月内使用5-氨基水杨酸类、硫嘌呤类、糖皮质激素或抗肿瘤坏死因子-α制剂者。结果显示父亲使用抗炎/免疫抑制药物与子代童年感染无显著关联。
要点
- 父亲受孕前使用5-氨基水杨酸类与子代1岁内感染风险降低相关(aHR 0.78,95%CI 0.66-0.91)。
- 父亲使用硫嘌呤类、糖皮质激素或抗TNF-α制剂与子代1岁内及1至3岁感染风险均无显著关联。
- 父亲受孕前使用抗炎/免疫抑制药物与子代童年感染无显著关联,填补了父亲用药安全性的研究空白。
核心结论
- 父亲在受孕前使用抗炎/免疫抑制药物与子代童年感染无显著关联,这些结果填补了父亲用药安全性的重要研究空白。
研究设计与样本
- 基于丹麦健康登记处的全国性队列研究,纳入1997年1月至2019年2月出生的、父亲患有炎症性肠病的所有活产单胎儿童。
- 暴露组为父亲在受孕前3个月内使用5-氨基水杨酸类、硫嘌呤类、糖皮质激素或抗肿瘤坏死因子-α制剂的儿童;非暴露组为未暴露于父亲炎症性肠病药物的儿童。
主要发现
- 共有2178名儿童的父亲暴露于5-氨基水杨酸类,843名暴露于硫嘌呤类,417名暴露于全身性糖皮质激素,436名暴露于抗TNF-α制剂;6799名儿童未暴露。
- 子代1岁内感染的风险比:5-氨基水杨酸类aHR 0.78(95%CI 0.66-0.91),硫嘌呤类aHR 0.89(95%CI 0.73-1.09),全身性糖皮质激素aHR 0.95(95%CI 0.70-1.29),抗TNF-α制剂aHR 1.17(95%CI 0.94-1.46)。
- 子代1至3岁感染的风险比:5-氨基水杨酸类aHR 0.97(95%CI 0.83-1.13),硫嘌呤类aHR 0.87(95%CI 0.71-1.07),全身性糖皮质激素aHR 1.25(95%CI 0.94-1.65),抗TNF-α制剂aHR 0.79(95%CI 0.60-1.03)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Information regarding the impact of paternal inflammatory bowel disease (IBD) medications on child outcomes is scarce. AIM: To examine the risk of childhood infections associated with fathers' use of anti-inflammatory/immunosuppressive medications taken before conception. METHODS: This is a nationwide cohort study based on Danish health registries, comprising all live-born singleton children born between January 1997 and February 2019 who were fathered by men with IBD. Exposed cohorts included children fathered by men treated with 5-aminosalicylates (5-ASAs), thiopurines, corticosteroids or anti-tumour necrosis factor-α (anti-TNF-α) agents within 3 months before conception. The unexposed cohort included children not exposed to paternal IBD medications. Outcomes were the first infection, diagnosed in the hospital setting in the first year of life, and from the age of 1 to 3 years. RESULTS: In all, 2178 children were fathered by men exposed to 5-ASAs, 843 to thiopurines, 417 to systemic corticosteroids and 436 to anti-TNF-α agents; 6799 children were unexposed. The adjusted hazard ratio (aHR) for infections within the first year of life for 5-ASAs was 0.78 (95% CI, 0.66-0.91), thiopurines 0.89 (95% CI, 0.73-1.09), systemic corticosteroids 0.95 (95% CI, 0.70-1.29), and anti-TNF-α agents 1.17 (95% CI, 0.94-1.46). The aHR for infections from 1 to 3 years for 5-ASAs was 0.97 (95% CI, 0.83-1.13), thiopurines 0.87 (95% CI, 0.71-1.07), systemic corticosteroids 1.25 (95% CI, 0.94-1.65), and anti-TNF-α agents 0.79 (95% CI, 0.60-1.03). CONCLUSION: Fathers' use of anti-inflammatory/immunosuppressive medications before conception was not significantly associated with childhood infections. These results fill an important research gap regarding paternal medication safety.
引用
- Friedman S, Garvik OS, Nielsen J, et al. Paternal use of medications for inflammatory bowel disease and the risk of hospital-diagnosed infections in the offspring: a nationwide cohort study. Aliment Pharmacol Ther. 2022. PMID: 35770457. doi:10.1111/apt.17113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。